Saya Ennai In The Management Of Eraippu Noi (Bronchial Asthma)
Phase 3
Completed
- Conditions
- Health Condition 1: J454- Moderate persistent asthma
- Registration Number
- CTRI/2022/02/040620
- Lead Sponsor
- ational Institute of Siddha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age between 18-60years.
Sex: Male ,Female &Transgender.
Patients with clinical symptoms of Sneezing, Rhinitis, Dyspnea, Cough with or without expectoration, Wheeze, Tightness of chest.
(Any of the above 5 symptoms would be present daily or twice or thrice in a week)
Patients who are willing to undergo Pulmonary Function Tests, radiological investigations and provide blood sample for lab investigations.
Exclusion Criteria
Having covid -19 (or) recent history of covid -19 infection
K/H/O other Lung diseases
K/H/O Cardiac diseases and Renal diseases
Sleep Apnea
Pregnancy
Lactation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PRIMARY OUTCOME: <br/ ><br>1.Primary outcome is assessed by comparing the lung volumes and capacities in pulmonary function tests along with graph PFT of obstructive pattern before and after treatment. <br/ ><br> <br/ ><br>Timepoint: 49th day <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method SECONDARY OUTCOME: <br/ ><br>1.Secondary outcome is assessed by comparing the improvement of clinical symptoms of Eraippu noi patients and laboratory parameters such as IgE, Absolute Eosinophil Count (AEC) before and after treatment.2.Quality of life in Eraippu noi (Bronchial Asthma) patients is assessed through Asthma Quality of Life Questionairre (AQLQ)Timepoint: 49th day